MorphoSys to Present Clinical Data on MOR103 at 2012 American College for Rheumatology Annual Meeting
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys to Present Clinical Data on MOR103 at 2012 American College for
Rheumatology Annual Meeting
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that the
Company's late-breaking abstract to present data from the phase 1b/2a clinical
trial evaluating its proprietary HuCAL antibody MOR103 in rheumatoid arthritis
at this year's American College for Rheumatology Annual Meeting has been
accepted. In addition to the safety and efficacy data published on September
20th, MorphoSys today published supplementary data from the phase 1b/2a trial
including EULAR response rates, changes in DAS28 scores as well as RAMRIS scores
used to analyze MRI imaging in RA trials.
In the randomized, double-blind, placebo-controlled phase 1b/2a trial in 96 mild
to moderate RA patients, MOR103 was administered in four weekly doses of 0.3
mg/kg, 1.0 mg/kg or 1.5 mg/kg. MOR103 showed excellent safety data at all doses
administered. With regards to efficacy, the trial was designed to look in
particular at the onset of the therapeutic effect. At week four, a significant
decrease of the DAS28 score was seen in the MOR103 group with a mean difference
of 1.12 and 0.61 in the 1.0 mg/kg and 1.5 mg/kg cohorts respectively, while an
increase of 0.17 was documented for placebo. EULAR response criteria were met in
68.2% of the 1.0 mg/kg dose group and in 69.5% of the 1.5 mg/kg dose group in
comparison to 7.4% in the placebo group. The clinical activity was mirrored by a
reduction in the RAMRIS score for joint swelling/synovitis of up to -1.5 within
4 weeks.
"We are very excited about the opportunity to present the data at this year's
American College for Rheumatology meeting, the most relevant medical conference
for RA. This is a major milestone for us," commented Dr. Arndt Schottelius,
Chief Development Officer of MorphoSys AG. "The additional clinical data we have
published today further underline the compound's potential to become an
important new drug in an area of unmet medical need."
The data will be presented by the principal investigator of the study, Prof.
Harald Burkhardt, Professor of Rheumatology and Head of the Division of
Rheumatology at Goethe University Frankfurt in a presentation session on
November 13, 2012.
The full abstract is available on http://www.acrannualmeeting.org/
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare. The
company's AbD Serotec unit uses HuCAL and other antibody technologies to
generate superior monoclonal antibodies for research and diagnostic
applications.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 70 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®
and 100 billion high potentials® are registered trademarks of MorphoSys AG
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary
of MorphoSys AG.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Alexandra Goller
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors(at)morphosys.com
Media Release (PDF):
http://hugin.info/130295/R/1653691/534825.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1653691]
Unternehmensinformation / Kurzprofil:
Datum: 06.11.2012 - 07:30 Uhr
Sprache: Deutsch
News-ID 199795
Anzahl Zeichen: 5740
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 173 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys to Present Clinical Data on MOR103 at 2012 American College for Rheumatology Annual Meeting"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
